Oncotarget
The cover for issue 1 of Oncotarget features Figure 7, "KEGG pathways," by Tschumper, et al.
TIL therapy and anti-CTLA4: can they co-exist? |
https://doi.org/10.18632/oncotarget.26509 Marie-Andrée Forget, Cara Haymaker, Rodabe N. Amaria, and Chantale Bernatchez |
1-2 |
PDF | How to cite | Order a Reprint |
Multidimensional intratumour heterogeneity in neuroblastoma |
https://doi.org/10.18632/oncotarget.26524 Kristoffer von Stedingk, David Gisselsson, and Daniel Bexell |
3-5 |
PDF | How to cite | Order a Reprint |
Role of acid sphingomyelinase-induced ceramide generation in response to radiation |
https://doi.org/10.18632/oncotarget.26526 Deepa Sharma, and Gregory J. Czarnota |
6-7 |
PDF | How to cite | Order a Reprint |
Phase 3 LILAC study sets standard for clinical evaluation of oncology biosimilars |
https://doi.org/10.18632/oncotarget.26528 Hans-Christian Kolberg, Gunter von Minckwitz, and Vladimir Hanes |
8-9 |
PDF | How to cite | Order a Reprint |
Combination of lenalidomide and vitamin D enhances MOR202-mediated cytotoxicity of macrophages: It takes three to tango |
https://doi.org/10.18632/oncotarget.26531 Cindy Flamann, Leonhard Busch, Andreas Mackensen, and Heiko Bruns |
10-12 |
PDF | How to cite | Order a Reprint |
Simplifying checkpoint inhibitor delivery through in vivo generation of synthetic DNA-encoded monoclonal antibodies (DMAbs) |
https://doi.org/10.18632/oncotarget.26535 Alfredo Perales-Puchalt, Elizabeth K. Duperret, Kar Muthumani, and David B. Weiner |
13-16 |
Abstract | PDF | Full Text | How to cite | Order a Reprint |
Clinical characteristics, treatment outcomes and potential novel therapeutic options for patients with neuroendocrine carcinoma of the prostate |
https://doi.org/10.18632/oncotarget.26523 Leonidas Apostolidis, Cathleen Nientiedt, Eva Caroline Winkler, Anne Katrin Berger, Clemens Kratochwil, Annette Kaiser, Anne-Sophie Becker, Dirk Jäger, Markus Hohenfellner, Clemens Hüttenbrink, Sascha Pahernik, Florian A. Distler, and Carsten Grüllich |
17-29 |
Abstract | PDF | Full Text | Supplementary Information | How to cite | Order a Reprint |
FGFR1β is a driver isoform of FGFR1 alternative splicing in breast cancer cells |
https://doi.org/10.18632/oncotarget.26530 Ming Zhao, Ming-Lei Zhuo, Xiaofeng Zheng, Xiaoping Su, and Funda Meric-Bernstam |
30-44 |
Abstract | PDF | Full Text | Supplementary Information | How to cite | Order a Reprint |
Role of miRNA in the regulation of cannabidiol-mediated apoptosis in neuroblastoma cells |
https://doi.org/10.18632/oncotarget.26534 Esraah Alharris, Narendra P. Singh, Prakash S. Nagarkatti, and Mitzi Nagarkatti |
45-59 |
Abstract | PDF | Full Text | How to cite | Order a Reprint |
Role of long non-coding RNAs in disease progression of early stage unmutated chronic lymphocytic leukemia |
https://doi.org/10.18632/oncotarget.26538 Renee C. Tschumper, Tait D. Shanafelt, Neil E. Kay, and Diane F. Jelinek |
60-75 |
Abstract | PDF | Full Text | Supplementary Information | How to cite | Order a Reprint |
Prospective clinical trial of 12-fraction carbon-ion radiotherapy for primary renal cell carcinoma |
https://doi.org/10.18632/oncotarget.26539 Goro Kasuya, Hiroshi Tsuji, Takuma Nomiya, Hirokazu Makishima, Yasuo Haruyama, Gen Kobashi, Kazuhiko Hayashi, Daniel K. Ebner, Tokuhiko Omatsu, Riwa Kishimoto, Shigeo Yasuda, Tatsuo Igarashi, Mototsugu Oya, Koichiro Akakura, Hiroyoshi Suzuki, Tomohiko Ichikawa, Jun Shimazaki, and Tadashi Kamada and the Working Group for Genitourinary Tumors |
76-81 |
Abstract | PDF | Full Text | How to cite | Order a Reprint |
Copyright © 2021 Impact Journals, LLC
Impact Journals is a registered trademark of Impact Journals, LLC